Phase 2 Randomized, Double-blind Clinical Trial to Evaluate Efficacy and Safety of the Ophthalmic Solution PRO-155 Versus Nevanac 0.1% Ophthalmic Solution in Post Phacoemulsification Patients
Latest Information Update: 07 Nov 2021
At a glance
- Drugs PRO 155 (Primary) ; Nepafenac
- Indications Ocular inflammation; Postoperative inflammation
- Focus Therapeutic Use
- Sponsors Laboratorios Sophia
- 19 May 2014 Trial status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 11 Apr 2014 New trial record